"Goserelin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
| Descriptor ID |
D017273
|
| MeSH Number(s) |
D06.472.699.327.740.320.340 D12.644.400.400.740.320.340 D12.644.456.460.315 D12.644.548.365.740.320.340 D12.776.631.650.405.740.320.340
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Goserelin".
Below are MeSH descriptors whose meaning is more specific than "Goserelin".
This graph shows the total number of publications written about "Goserelin" by people in this website by year, and whether "Goserelin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Goserelin" by people in Profiles.
-
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504.
-
Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo. Nanomedicine. 2015 Jul; 11(5):1277-83.
-
Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65.
-
Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice. Fertil Steril. 2014 Apr; 101(4):1157-64.e1.
-
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer. 2013 Dec; 11(4):407-15.
-
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25.
-
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):540-5.
-
Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol. 2013 Jan; 24(1):133-8.
-
Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012 Jul 18; 104(14):1059-67.
-
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012 Mar; 79(3):633-7.